Navigation Links
CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Date:4/26/2012

in the recall or seizure of previously cleared or approved tissues and products, our HemoStase sales ceased in late March 2011, and we will not be able to participate in the hemostats market in the U.S. or other markets where we lack regulatory approval unless we can obtain FDA or other regulatory approval for PerClot, we may not be successful in obtaining necessary clinical results and regulatory approvals for services and products in development, and our new services and products may not achieve market acceptance, uncertainties related to patents and protection of proprietary technology may adversely impact the value of our intellectual property, intense competition may impact our ability to operate profitably, if we are not successful in expanding our business activities in international markets, we may be unable to increase our revenues, we are dependent on the availability of sufficient quantities of tissue from human donors, key growth strategies may not generate the anticipated benefits, investments in new technologies and acquisitions of products or distribution rights may not be successful, regulatory action outside of the U.S. has affected our business in the past and may affect our business in the future, consolidation in the healthcare industry could continue to result in demands for price concessions, limits on the use of our tissues and products, and limitations on our ability to sell to certain of our significant market segments, extensive government regulations may adversely impact our ability to develop and market services and products, the success of many of our tissues and products depends upon strong relationships with physicians, our existing insurance policies may not be sufficient to cover our actual claims liability, we may be unable to obtain adequate insurance at a reasonable cost, if at all, we are not insured against all potential losses, and natural disasters or other catastrophes could adversely impact our business, financial condition
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
2. CryoLife Enhances Management Team with Promotions
3. CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
4. CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
5. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
7. CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
8. CryoLife Provides Update on ValveXchange®, Inc. Investment
9. CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
10. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
11. CryoLife Makes Equity Investment in ValveXchange® Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... SHENZHEN, China, Aug. 28, 2014 China ... ("Nepstar" or the "Company"), a leading retail drugstore ... directly operated stores, today announced its unaudited financial ... Financial HighlightsFor the quarter ended June 30, ... RMB686.6 million (US$110.7 million) compared to RMB638.8 million in ...
(Date:8/27/2014)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. , (OTCQB: DMPI), developer of advanced ... company at the 16th Annual Rodman & Renshaw Global ... Co., LLC. The presentation will take place Tuesday, September 9th ... (4th floor) at the New York Palace Hotel in ...
(Date:8/27/2014)... BURLINGTON, Mass. , Aug. 27, 2014 /PRNewswire/ ... six different specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, ... of clinical trials that a biosimilar has been ... which biosimilar product they choose to prescribe. ... Advisory Service report entitled Acceptance of ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2
(Date:8/28/2014)... Hastings and Hastings, a Phoenix Arizona ... in the industry is pleased to report having saved ... approximately $125,000. This is exciting news for existing clients ... well defined proof that Hastings and Hastings stands behind ... fees. Saving clients money when it comes to settlements ...
(Date:8/28/2014)... 28, 2014 InventHelp, a ... clients, an inventor from California, has designed an alternative ... invention is patented. , The “Abdominal Swimming Support” is ... risk of injuries from physical activity if one is ... or muscular atrophy. Ideal for use as a ...
(Date:8/28/2014)... Baltimore, MD (PRWEB) August 28, 2014 ... has received Diamond level Allergan Privilege Program status ... widely used treatments as Botox, Juvederm, and Voluma. Maryland ... exemplary and prolific use of these treatments. The dermatologists ... in injectable treatments, and are one of the leading ...
(Date:8/28/2014)... 2014 Altec Products, Inc., a ... announced today that they have been awarded the ... of the International Association of Microsoft Channel Partners ... founded in 1994, providing Microsoft Partners with a ... community at large while facilitating mutual growth and ...
(Date:8/28/2014)... 2014 Dr. Bryan McIntosh of Bellevue, ... guide to the tummy tuck cosmetic procedure, leading ... procedure itself, and how to recover well afterwards. ... Dr. McIntosh also discusses how to have accurate expectations ... the procedure is as successful as possible. , To ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 3Health News:InventHelp® Client Patents “Abdominal Swimming Support” – Invention Could Serve as an Alternative Flotation Device 2Health News:Maryland Laser Skin and Vein Receives Diamond Status From Allergan 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... healthy lifestyle that includes not smoking, limiting alcohol intake, and ... the journal PLoS Medicine , Wei Zheng, M.D., Ph.D., ... results from a large study quantifying the impact of combining ... lifestyle pattern being normal weight, having low belly fat, ...
... study released today by the American Lung Association, and ... helping smokers quit not only saves lives but also ... titled Smoking Cessation: the Economic Benefits, provides a nationwide ... smoking with the economic benefits of states providing cessation ...
... New research findings from the Universit de Montral reveals ... understand and use irony. This study, published recently in ... way parents communicate with their family. "Previous studies ... eight or ten," says Stephanie Alexander, a postdoctoral student ...
... really takes for seniors to make ends meet in each ... state Capitol in Sacramento. The release is ... (Elder Index), a tool that measures the actual costs of ... replacing federal poverty level (FPL) guidelines as a new standard ...
... HealthDay Reporter , TUESDAY, Sept. 14 (HealthDay News) ... when in vitro fertilization is done during the springtime. ... highest in the spring -- 73.5 percent vs. 67.9 ... than the summer and fall rates. "Epidemiolgists have ...
... TUESDAY, Sept. 14 (HealthDay News) -- The risk of tendon ... higher levels of estrogen, a small European study suggests. ... to test estrogen levels in order to identify at-risk athletes ... training program, said Katherine E. Burgess, of the University of ...
Cached Medicine News:Health News:Benefits of healthy lifestyle factors stronger in combination 2Health News:New study finds positive return on investment for states that invest in quit smoking treatments 2Health News:New study finds positive return on investment for states that invest in quit smoking treatments 3Health News:Report shows federal poverty guidelines leave state's seniors destitute 2Health News:Report shows federal poverty guidelines leave state's seniors destitute 3Health News: In Vitro Fertilization Success Rate Higher in Spring, Study Suggests 2Health News: In Vitro Fertilization Success Rate Higher in Spring, Study Suggests 3
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
Medicine Products: